IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Rubicon Research IPO is a Book building listing on BSE,NSE exchange, with an ipo size of ₹ [●] Cr. The company is based in Mumbai and caters to Pharmaceutical sector. Axis Capital , Iifl Securities , Jm Financial , SBI Capital Markets are the merchant bankers of Rubicon Research IPO. It is a MainBoard Upcoming IPO which filed its Draft Red Herring Prospectus (DRHP) on 31st July 2024.
Rubicon Research IPO posted revenues of ₹ 872.38 crores and PAT of ₹ 91.01 crores in FY25 on annualised basis.
Revenue:
₹ 853.80 Cr.
EBITDA Margin:
20.26
% 
Net Worth: ₹ 385.00 Cr.
Market Capitalisation:
[●]
P/E:
[●]
P/BV: [●]
EV/EBITDA: 2.00 times
Financial results of Rubicon Research IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
| Financials | FY24 | FY23 | FY22 | ||
|---|---|---|---|---|---|
|
Balance Sheet
|
|||||
| Assets | 1109.40 | 749.70 | 559.50 | ||
| Net Worth | 385.00 | 286.30 | 305.30 | ||
| Total Debt | 396.40 | 317.80 | 169.40 | ||
|
Profit & Loss
|
|||||
Revenue
Revenue on annualised basis |
853.80 | 393.50 | 131.50 | ||
EBITDA
EBITDA on annualised basis |
173.00 | 43.90 | -22.30 | ||
PAT
PAT on annualised basis |
9.10 | -16.80 | -67.10 | ||
Rubicon Research IPO PAT Margin is 1.07 % , ROCE (Return on Capital Employed) is 18.62 % as per latest financial. The below table shows Rubicon Research IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
| Particulars | FY24 | FY23 | FY22 |
|---|---|---|---|
| EBITDA Margin (%) | 20.26 | 11.16 | -16.96 |
| PAT Margin (%) | 1.07 | -4.27 | -51.03 |
| EPS (₹) | 5.98 | -1.11 | -4.11 |
| ROE (%) | 2.36 | -5.87 | -21.98 |
| ROCE (%) | 18.62 | 1.35 | -12.68 |
| ROA (%) | 0.82 | -2.24 | -11.99 |
| Debt to Equity | 1.03 | 1.11 | 0.55 |
The market Capitalisation of Rubicon Research IPO is ₹ [●] crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Rubicon Research IPO prospectus highlights an Return on Equity (ROE) of 15 %, Return on Assets (ROA) of 12 %, and an EBITDA Margin of 18 %, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Rubicon Research IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Rubicon Research IPO is ₹ [●] Cr., based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Rubicon Research IPO has a Price-to-Earnings (PE) ratio of [●], indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Rubicon Research IPO reported revenue of ₹ 872.38 Cr. in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Rubicon Research IPO provide insights into sales growth, market demand, and business scalability.
Rubicon Research recorded an EBITDA of ₹ 173.00 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Rubicon Research Profit After Tax (PAT) is ₹ 9.10 Cr., reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 853.80 Cr.
EBITDA Margin:
20.26
%
Net Worth: ₹ 385.00 Cr.
Market Capitalisation:
[●]
P/E:
[●]
P/BV: [●]
EV/EBITDA: 2.00 times
Rubicon Research operates in Pharmaceutical and . The Issue is listed on BSE,NSE in May, 2025. Rubicon Research IPO size was with Issue price of .
Merchant Banker(s) of Rubicon Research IPO: Axis Capital Limited , Iifl Securities Limited , Jm Financial Limited , SBI Capital Markets Limited
Rubicon Research IPO subscription was X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Rubicon Research IPO listed at a listing price of against the offer price of .
The current market price of Rubicon Research is .
Why Us?
